Stem cells are considered a valuable cellular resource for tissue replacement therapies in most brain disorders. Stem cells have the ability to self-replicate and diff erentiate into numerous cell types, including neurons, oligodendrocytes and astrocytes. As a result, stem cells have been considered the "holy grail" of modern medical neuroscience. Despite their tremendous therapeutic potential, little is known about the mechanisms that regulate their diff erentiation. In this review, we analyze stem cells in embryonic and adult brains, and illustrate the diff erentiation pathways that give origin to most brain cells. We also evaluate the emergent role of the well known anti-oxidant, vitamin C, in stem cell diff erentiation. We believe that a complete understanding of all molecular players, including vitamin C, in stem cell diff erentiation will positively impact on the use of stem cell transplantation for neurodegenerative diseases.
STEM CELLS DURING BRAIN DEVELOPMENT AND ADULT LIFE
Early during embryogenesis, a layer of neuroepithelial cell folds and fuses to form the neural tube, a well characterized anatomical structure that gives rise to most brain regions (Geelen and Langman, 1979; Ray and Niswander, 2012) . Thus, neuroepithelial cells are the primordial neural stem cells of the embryonic brain. These cells have three distinguishable features: i) highly polarized, they face both the ventricular zone (VZ) and the pial surface (Huttner and Brand, 1997) ; ii) expression of the intermediate fi lament, nestin (Lendahl et al., 1990) ; and iii) ability to undergo inter-kinetic nuclear migration, a phenomenon involved in the determination of neural progenitors (Del Bene et al., 2008; Taverna and Huttner, 2010) .
In the neural tube, neuroepithelial cells are capable of proliferating actively and symmetrically to increase their population (Egger et al., 2011; Tawk et al., 2007) . As development continues, these cells begin to experience asymmetrical divisions, which lead to the generation of the first neuroblasts and basal progenitors, initiating the embryonic neurogenesis process (Haubensak et al., 2004; Kriegstein and Alvarez-Buylla, 2009) . Following the onset of neurogenesis, at embryonic days 9-10 in mice (E09-E10), neuroepithelial cells experience several molecular and morphological changes that transform them into a new type of cell, the radial glia. These new progenitor cells uniformly extend a long radial process from the cell body, located at the VZ, all the way to the most external portion of the cortex, the pial surface (Gotz and Huttner, 2005; Morrens et al., 2012; Yamasaki et al., 2001) . Such morphological changes coincide with the expression of diff erent markers, including GLutamate ASpartate Transporter (GLAST), Brain Lipid-Binding Protein (BLBP), Tenascin-C and Glial Fibrillary Acidic Protein (GFAP), which is absent in rodents (Anthony et al., 2004; Hartfuss et al., 2001; Malatesta et al., 2003) . Some proteins are highly enriched in radial glial cells. For example, Radial Glia 1 and 2 (RC1 and RC2) are two proteins specifi c to these cells alone (Edwards et al., 1990) . The protein 3-phosphoglycerate dehydrogenase (3-PGDH), a key enzyme for L-serine biosynthesis, is also characteristically expressed in radial glia (Yamasaki et al., 2001) . Using immunohistochemical methods, we show the presence of 3-PGDH, in radial glial cells of both E15 embryonic mouse cortex and human cortex at 9 weeks gestation ( Figure  1A ,B).
Through continuous asymmetrical divisions, radial glial cells give rise to intermediate precursors and neuroblasts (Malatesta et al., 2000) that will then generate most neuronal classes (e.g., pyramidal, stellate, etc). Soon thereafter, these radial glia derived-newborn neurons will use the same radial glial processes as scaffolds to migrate to the appropriate cortical layers (Noctor et al., 2002) (Figure 1C ).
Close to the perinatal period, radial glial cells stop producing neurons and diff erentiate into astrocytes (Culican et al., 1990) . In the presence of appropriate trophic factors, radial glial cells in culture diff erentiate into neuronal and glial cells (Liu and Lauder, 1992; Yamasaki et al., 2001) . Interestingly, the number of each diff erentiated cell type (neuron or glia) depends on the time at which radial glial cells are isolated for the in vitro studies. For example, neuronal formation is favored by radial glia obtained between embryonic days 13- 16 (E13-E16) while glia generation is promoted by radial glial taken at later stages (embryonic day 18 to postnatal days) (Malatesta et al., 2000; Temple, 2001) .
Between postnatal days 1-15 (PN1-PN15), most radial glial cells disappear from almost all brain regions (Tramontin et al., 2003) . Radial glia-like cells are however maintained in specifi c regions of the brain. For instance, the Bergmann glia is a radial glia-like cell that is predominant in cerebellar cortex.
These cells like radial glia present high levels of GFAP and S100 protein expression (Figure 2A-D) , generate neuronal and glial progenitors and participate in the migration of newborn granule cells. Such neurogenic activity disappears at later stages of postnatal development. Tanycytes represent another radial glial cell in the hypothalamus ( Figure 2E -G). Unlike most radial glial cells, tanycytes maintain their neurogenic activity even in the adult brain (Cifuentes et al., 2011; Lee et al., 2012) , the reason by which they are considered atypical stem cells. Tanycytes play a major role in the formation of the median eminence-cerebrospinal fl uid barrier ( Figure 2E ). More recently, these cells have been found to be crucial for the brain glucose sensing mechanism (Cortes-Campos et al., 2011; Orellana et al., 2012) .
Perhaps the most active neurogenic site present in the mature brain is concentrated in the ventricular wall of lateral ventricle. These radial glial-like stem cells or Type B cells show intense expression of GFAP ( Figure 3A-D) , maintaining long basal processes in contact with blood vessels ( Figure 3E ) like radial glial cells. Type B cells are close to ependymal cells, which produce factors that regulate neuronal production; they generate Type C cells, which then proliferate to form Type A cells or neuroblasts (Alvarez-Buylla et al., 1998; Doetsch et al., 1997; Garcia-Verdugo et al., 1998) (Figure 3A ). Diff erent studies have shown that the structure of these neurogenic sites is variable across species. For example, in guinea pig brain, we observed an ependymal cell layer positive for Isolectin B4 expression within the subventricular zone ( Figure 3F , arrows). Additionally, in the subventricular zone it is possible to fi nd a ribbon of Type B cells ( Figure 3F) . A similar cellular Post-natal cerebellar frontal section of mouse brain immunostained using specifi c antibodies anti-GFAP or anti-S100, and two different secondary antibodies labeled with Cy2 or Cy3, respectively. The Bergmann glial process and the end-terminal on meninges (A, arrow) were positive (B-D, arrows). (E-G) Tanycytes from the median eminence analyzed using scanning electron microscopy on the ventricular surface, showing the cerebrospinal fl uid-median eminence barrier. The processes of these cells are detected using anti-vimentin and a Cy2-labeled secondary antibody. Propidium iodide was used for nuclear staining. The image was processed using the software Imaris. One tanycyte is depicted in yellow in G. III-V, third ventricle. PT, pars tuberalis. Scale bars: 20μm.
organization is observed in the subventricular zone of the human brain (Sanai et al., 2004) . In these niches the neuroblasts migrate between Type B and ependymal cells ( Figure 3H -I, arrows). Therefore, neurogenic niches seem to present diff erent structures depending on the species studied (Chojnacki et al., 2009 ).
STEM CELL DIFFERENTIATION: CELLULAR SIGNALING
How do radial glial cells regulate their fate to fi rst generate neurons and then astrocytes? Experimental evidence suggests that both internal and external signals trigger neurogenesis and gliogenesis (Behar et al., 1994; Colombo et al., 1993; Jiang et al., 1998; Liu and Lauder, 1992; Yamasaki et al., 2001) . Once these signals become available in quantities above the activation threshold, radial glial cells respond by diff erentiating towards a defi ned cell type. Along with these signals, diff erent genetic programs are activated, allowing radial glial cells to express receptors and proteins necessary to respond specifi cally to the external stimuli (Ciccolini, 2001; Okano and Temple, 2009; Qian et al., 2000) . Of the signals that promote neuronal diff erentiation, the helix-loop-helix type transcription factors, neurogenin 1 and 2 (Ngn1 and Ngn2); (Guillemot et al., 1993; Ma et al., 1996; Ma et al., 1998; Sommer et al., 1996) , Mash1 (Guillemot et al., 1993; Nieto et al., 2001) , Math (Gradwohl et al., 1996; Kageyama et al., 2005) and NeuroD (von Bohlen und Halbach, 2011) , are among the most well-studied. Ngn1 is a factor primarily expressed during the neurogenic period (B and D) . The processes were in contact with the blood vessel of the subventricular zone (E). (F-I) Adult guinea pig frontal brain section of the lateral ventricle neurogenic area immunostained using specifi c antibodies anti-tubulin βIII (red) or anti-GFAP (blue), and two different secondary antibodies labeled with Cy3 or Cy5, respectively. The ependymal cells were observed by using Isolectin B4-FITC labeled (green, arrowheads). The astrocytes or Type B cells form a ribbon in the subventricular zone (F). The neuroblasts are detected near the ependymal cells (G-H, arrows). The neurogenic niche structure observed in guinea pig (I) is similar to the neurogenic niche previously described in adult human brain. Bv, blood vessels; LV, lateral ventricle. Scale bars: 20μm.
in the cortex (Fode et al., 2000) . Because it induces neuronal differentiation but also inhibits glial differentiation by interfering with the glial signaling pathway JAK/STAT (Sun et al., 2001) , it is recognized as a factor capable of modifying neural stem cell fate. Ngn2 is primarily a neurogenic factor expressed in a small population of neural stem cells, and cells that lack Ngn2 requires the presence of Mash1 to generate neurons (Nieto et al., 2001) .
Little is known about the extracellular factors that regulate neurogenesis. Recent work indicates that sonic hedgehog (Shh) regulates neurogenesis by directly modulating Ngn1 expression (Ota and Ito, 2003) . Neurotrophin 3 (NT3), a factor expressed in the ventricular zone, has also been implicated in neurogenesis (Ohtsuka et al., 2009 ). Once NT3 is released to the extracellular medium, it activates the ERK1/2 signaling pathway, which ultimately leads to the activation of transcription factors that control neuronal diff erentiation (Bartkowska et al., 2010; Ohtsuka et al., 2009) .
Several factors are known to induce gliogenesis. For example, Notch1 is a membrane receptor expressed in most neural stem cells that upon activation by its Jagged or Delta ligands (Zhou et al., 2010) leads to a cascade of proteolytic events, which culminates with the translocation of its internal domain to the nucleus. In the nucleus, Notch1 acts as a transcriptional transactivator (Morrison et al., 2000; Zhou et al., 2010) , inducing demethylation of the binding sites for STAT proteins, such as the promoter of the GFAP and S100B gene. This allows radial glial cells to respond to the JAK/ STAT signaling cascade, a well established gliogenic pathway (Freeman, 2010) . Factors, such as ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and cardiotrophin 1 (CT1), also regulate gliogenesis. After binding to their respective receptors, each factor activates the JAK/STAT signaling cascade that leads to GFAP expression, a well known marker for glia (Barnabe-Heider et al., 2005; Bhattacharya et al., 2008; Bonni et al., 1997) .
Growth factors, such as basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), are widely used to maintain stem cells in culture; they also participate in stem cell diff erentiation (Chojnacki et al., 2009) . At the onset of neural development, receptors for bFGF are highly enriched in radial glial like stem cells. Interestingly, a large fraction of these receptors are associated with a variety of proteoglycans present in the extracellular matrix (Thisse and Thisse, 2005) . Mechanistically, the receptors may uptake the bFGF from the extracellular matrix (Aigner et al., 2002) , and upon activation, collaborate in the determination of astrocytic lineage. At present, it is necessary to understand the dynamical relationships between extracellular signals and transcriptional factors. For example, in high concentrations of Ngn1, BMP2 promotes neuronal diff erentiation. On the contrary, if Ngn1 levels fall, BMP2 promotes gliogenesis (Nakashima et al., 2001 ). Therefore, studying the different combinations that occur over time might provide insights into the patterns of cellular diff erentiation.
ROLE OF VITAMIN C IN NEURAL STEM CELL DIFFERENTIA-TION
Over the years, we have biochemically characterized vitamin C function in brain tissue. Known as a critical antioxidant, recent results suggest that vitamin C plays an important role in stem cell physiology. To gain a deeper understanding into this novel role, we have critically revised the role of vitamin C in stem cell generation, proliferation and diff erentiation. Although the mechanisms by which vitamin C modulates stem cell biology are unclear, the revision presented here suggests a unique role for vitamin C during stem cell transplantation in a number of brain diseases.
Vitamin C in the central nervous system
Most mammals are able to synthesize vitamin C from glucose. Humans and primates however are defi cient in the enzyme that catalyzes vitamin C biosynthesis (L-.gulonolactone oxidase); therefore, they must obtain it from the diet (Nishikimi and Yagi, 1991) . Lack of vitamin C during development and/ or adulthood can produce severe physiological disorders that could lead to death, implying that as micronutrient, vitamin C is essential for the normal functioning of the organism (Harrison and May, 2009; Rice, 2000; Tveden-Nyborg et al., 2009) . Its best known role is that of an antioxidant agent, taking away highly reactive free radicals that are constantly generated by the cellular machinery (Arrigoni and De Tullio, 2002; Harrison and May, 2009; Nualart et al., 2003; Wayner et al., 1986 ). This role is highly relevant for both the maintenance of cerebral functions and protection of brain structures (Rice, 2000) . Given that the brain is among the organs with the highest rate of metabolism, it is subjected to elevated levels of oxidative stress, and thus high levels of vitamin C are required.
In addition to its protective role, vitamin C acts as a cofactor in several enzymatic reactions. It participates in the synthesis of catecholamines, carnitine (Rebouche, 1991), cholesterol, amino acids, and several other hormonal peptides (Glembotski, 1987) . It also facilitates the hydroxylation of proline and lysine residues in collagen, which are required for its correct folding (Murad et al., 1981; Peterkofsky, 1972 Peterkofsky, , 1991 as well as the hydroxylation of hypoxiainducible factor-1 alpha (HIF1a), which is degraded by the proteosome under normal oxygen conditions (Harrison and May, 2009 ). Recent investigation indicates that vitamin C modulates dopaminergic, glutamatergic and cholinergic neurotransmission (Rebec and Pierce, 1994; Sandstrom and Rebec, 2007) .
Vitamin C can also promote myelin formation (Eldridge et al., 1987) . Using adult salamander dorsal root ganglia, Olsen and Bunge (1986) observed myelination in vitro and described vitamin C as a critical factor for Schwann cell myelination. Similarly, Eldridge et al. (1987) described that chick embryo extracts and L-AA led to the formation of large quantities of myelin and to the assembly of basal laminae. They strongly suggest that AA promotes Schwann cell myelin formation. Furthermore, in vitro and animal studies showed that AA improves the clinical and pathological phenotype of a mouse model of Chercot-Marie-tooth disease 1A (CMT1A) (Kaya et al., 2007; Passage et al., 2004) , which led to various clinical trials examining AA administration in CMT1A. However, none of these trials showed a signifi cant benefi t of AA in the treatment of CMT1A patients (Burns et al., 2009; Micallef et al., 2009; Verhamme et al., 2009 ). The lack of eff ectiveness in the treatments was diffi cult to interpret because there were no studies assessing SVCT2 expression in Schwann cells and peripheral nerves, data that was recently obtained by (Gess et al., 2010) . Additionally, they used the heterozygous SVCT2+/-mice to elucidate the functions of SVCT2 and AA in the murine peripheral nervous system. SVCT2 defi ciency causes hypomyelination and extracellular matrix defects in peripheral nervous system (Gess et al., 2011) . Also, they demonstrated that expression of various collagen types was reduced in the sciatic nerves of SVCT2 +/-mice, and hydroxyproline levels were surprisingly normal. These results indicate that collagen formation was regulated on the transcriptional and not the posttranslational level (Gess et al., 2011) .
Vitamin C transporters in the brain
Two types of proteins are required for the uptake and maintenance of vitamin C levels in the brain: the sodiumascorbate co-transporters (SVCTs) and the hexose transporters (GLUT1, GLUT3, GLUT4), the latter incorporating only the oxidized form of vitamin C (Nualart et al., 2003; Rumsey et al., 2000; Rumsey et al., 1997; Vera et al., 1993) . Therefore, SVCTs are the major homeostatic regulators of vitamin C levels in the central nervous system (CNS; Rice, 2000), actively uptaking its reduced form, L-ascorbate (Caprile et al., 2009; Castro et al., 2001; Garcia et al., 2005) . L-ascorbate is transported against its concentration gradient ( Daruwala et al., 1999; Tsukaguchi et al., 1999) , and thus the energy required for the transport is supplied by sodium exchange through the Na + /K + -ATPase pump (Castro et al., 2001) . The relationship between sodium and ascorbate transport was found to be 2:1, and the order of union to the substrate was sodium-ascorbate-sodium (Godoy et al., 2007) . At the molecular level, two SVCTs (SVCT1 and SVCT2) encoded by different genes have been described Figure 4 . SVCT2 mRNA detection by in situ hybridization in adult brain: SVCT2 expression at the mRNA level by in situ hybridization using digoxigenin-labeled cRNA probes specifi c for SVCT2. An intense hybridization signal was observed in different neurons of the mouse brain, the most intense signal was detected in hippocampus, thalamic nuclei, hypothalamus and the entorhinal cortex (A, B, C). No labeling was detected in endothelial cells of the blood-brain barrier and astrocytes. To confi rm the presence of negatively-labeled astrocytes in the tissue sections, we carried out in situ hybridization for SVCT2 in combination with immunohistochemical analysis using antibodies against GFAP and a peroxidase-labeled secondary antibody (D-E, arrows). Most astrocytes were negative for SVCT2 in the different areas of the brain (B-C); however, the astrocytes detected in the external area of the entorhinal cortex and marginal zone of the brain showed SVCT2 expression (C, D and E, arrows). Experiments using an antisense for SVCT2 and anti-GFAP in the same section confi rmed SVCT2 expression in GFAP-positive cells (C and E, arrows). F, Control experiments using a sense riboprobe. Scale bars: 20μm. Faaland et al., 1998; Tsukaguchi et al., 1999; Wang et al., 1999) . Each transporter has a distinct distribution. For example, in situ hybridization and immunohistochemical experiments have shown that SVCT2 is expressed mostly in CNS within choroid plexus cells (Garcia et al., 2005; Tsukaguchi et al., 1999) , embryonic neurons (Castro et al., 2001) , tanycytes (Garcia et al., 2005) and adult cortical and hippocampal neurons (Astuya et al., 2005) (Figure 4A-B) . Although most astrocytes do not express SVCT2, our results indicate that astrocytes of the external area of the entorhinal cortex express SVCT2 ( Figure  4C,E) . Additionally, glia limitans, the thin barrier of astrocytes associated with the parenchymal basal lamina surrounding the brain, also showed double labeling for SVCT2 and GFAP ( Figure 4C-E, arrows) . In contrast, SVCT1 is typically found in peripheral organs, such as kidney, intestine, or liver (Castro et al., 2008; Tsukaguchi et al., 1999) . Cloned for the fi rst time by Tsukaguchi et al. (1999) , both transporters share an amino acid identity sequence of 60-65%, and according to predictions of hydrophobicity, each has 12 transmembrane domains with the N-and C-terminal domains facing the cytosolic side (Savini et al., 2008) . SVCT1 and SVCT2 have "non-functional" variants generated by alternative splicing. In the case of SVCT2, Lutsenko et al. (2004) described a short isoform that lacks the transmembrane segment of domains 4, 5 and 6 (Lutsenko et al., 2004) . This isoform acts as a dominant negative when inhibiting the transport of ascorbate mediated by the complete isoform of SVCT2. The expression of both SVCTs is regulated at diff erent levels: transcriptionally by the presence of two promoting sequences with distinct effi ciencies in SVCT2, and post-transductionally by the presence of phosphorylation and glycosylation sites in SVCT1 and SVCT2. Recently, these cellular modifi cations were described as determinant of the functionality and subcellular localization of these transporters (Subramanian et al., 2008) .
Diff erent research groups have shown the physiological importance of both transporters. Sotiriou et al. (2002) generated knockout mice for the gene encoding SVCT2, and observed that animals developed respiratory problems and cerebral hemorrhages dying within minutes immediately after birth. Biochemical analysis showed that vitamin C levels in brain and other areas were undetectable, indicating that SVCT2 is critical for the maintenance of vitamin C levels. The cerebral hemorrhages observed in these animals suggest poor formation of collagen, which requires vitamin C as cofactor for its synthesis (Sotiriou et al., 2002) . Histological analysis showed no morphological alterations at the cerebral level, suggesting that SVCT2 is not required at least in part for brain development. The above leaves open the possibility that other isoforms of the transporter not yet identifi ed contribute to the incorporation of vitamin C to trigger the diff erentiation of cerebral cells.
Vitamin C and stem cell diff erentiation
Recently, Pei and colleagues (2010) found that vitamin C favored the generation of induced pluripotent stem cells (iPS) (Esteban et al., 2010) . Cells grown in vitro in the presence of vitamin C expressed two histone demethylases, Jhdm1a and Jhdm1b (Wang et al., 2011) , which are required for iPS cells production. Vitamin C also helped to maintain iPS cells in vitro, which favored their proliferation (Esteban et al., 2010) . The increase in the number of iPS was found to be mediated at least in part by a reduction in the levels of p53, the tumor suppressor protein that elicits cell death (Esteban et al., 2010) . Together, these results suggest that vitamin C is able to positively regulate stem cell generation and proliferation.
Neural tissue has been shown to attain ascorbic acid (AA) concentrations that rank among the highest of mammalian tissues (Horning et al., 1975; Kratzing et al., 1982; Milby et al., 1982) . In fact, vitamin C levels are particularly high in fetal rat brain, doubling from the 15th to the 20th day of gestation and then dropping signifi cantly by the time of birth (Kratzing et al., 1985) . A similar pattern was observed in chicken embryos in which the AA concentration increased to 5.6 nmol/mg by D10 in ovo, and gradually declined to 32% before birth (Wilson, 1990) . Surprisingly, normal brain diff erentiation has been observed in SVCT-null mice, suggesting that embryonic cells may use diff erent mechanisms or transporters to take up and maintain high levels of vitamin C (Sotiriou et al., 2002) . Recently, Yan and collaborators (Yang et al., 2001 ) reported high expression of SVCT2 in embryonic mesencephalic neurons, and suggested an important role for vitamin C in dopaminergic diff erentiation. They observed that the stem cells grown with AA gave rise to a 10-fold increase in the number of dopaminergic neurons compared to the untreated cultures (Yang et al., 2001) .
To characterize the localization of the vitamin C transporter, SVCT2, in early brain development, the expression of SVCT2 was examined through RT-PCR in fetal mouse brain. High levels of SVCT2 expression were observed in the cerebellum, hippocampus, and hypothalamus (Castro et al., 2001) . Kinetic analysis of AA uptake in primary neuronal cultures showed two affi nity constants, 8 and 103 uM. The fi rst kinetic constant is in accordance with previous reports for SVCT2 (Tsukaguchi et al., 1999) . The second kinetic constant suggests an alternative path for the transport of vitamin C in mouse embryonic neurons. Because the sole presence of a given mRNA does not always correlate with protein expression and functional activity, it is, therefore, necessary to study both mRNA expression and protein distribution to obtain a more defi nitive answer regarding the expression and localization of SVCT2 in fetal rat brain. By a variety of methods, Caprile and collaborators demonstrated that SVCT2 is highly expressed in the ventricular and subventricular areas of fetal rat brain. Further functional analysis carried out in immature neurons isolated from either embryonic brain cortex or cerebellum showed that SVCT2 is localized in the cellular membrane and is involved in vitamin C uptake in these cells (Caprile et al., 2009 ). Similar results have been obtained in Neuro2a and HN33.11 cell lines, demonstrating that SVCT2 is critical for vitamin C transport (Caprile et al., 2009 ). In line with our hypothesis, SVCT2 has also been implicated in neuronal maturation possibly by regulating the differentiation of embryonic cortical precursors into neurons and astrocytes. AA promoted in vitro diff erentiation of CNS precursor cells into neurons and astrocytes in a cell density-dependent manner (Lee et al., 2003) . Also, AA seems to aff ect the functional maturation of post-mitotic neurons. For example, the addition of AA to these neurons enhanced the frequency and amplitude of synaptic potentials, an eff ect that was dose-dependent and highly specifi c (Lee et al., 2003 ). An AA-dependent increase in the expression of genes, which could potentially compound the eff ects of AA on cell diff erentiation, was also observed (Qiu et al., 2007) , suggesting that AA may stimulate the brain in the generation of CNS neurons and glia. It has also been observed that in cultured hippocampal neurons, SVCT2 was required for normal maturation of glutamatergic function (Qiu et al., 2007) . Hippocampal neurons from days 16-18 in utero Slc23a2-/-and wild-type embryos were isolated from mice and functionally compared. It was consistently seen that the lack of SVCT2 resulted in smaller amplitude of synaptic potentials, and these mice also exhibited less complexity in terms of number of primary dendrites as well as total dendrite length (Qiu et al., 2007) . Hippocampal neurons from Slc23a2-/-embryos lack AA while the intracellular concentration in wild-type neurons was within the range of 0.1-0.2mM (Qiu et al., 2007) .
How does vitamin C promote stem cell diff erentiation? How do neural stem cells, or any other pluripotent cell, uptake vitamin C? What set of transporters are present in these cells? The answers to these questions are necessary to understand the role of vitamin C in neural stem cell diff erentiation.
ROLE OF VITAMIN C IN BRAIN STEM CELL TRANSPLANTA-TION

Stem cell transplantation in the CNS
Stem cell transplantation has emerged as a unique therapeutic strategy for most neurological disorders (i.e., Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), stroke, etc.). The goal of this strategy is the partial or complete replacement of damaged or dead neural cells by newer and healthier ones, which in theory should lead to functional restoration of the affl icted tissue. Depending on the type of cells used (e.g., induced pluripotent, embryonic or adult stem cells), their physiological and metabolic state and the disease to be targeted, stem cell transplantation therapy has obtained promising results (see below). The low number of cells transplanted, their limited survival, decreased diff erentiation efficiency, poor cellular integration, in addition to tissue immune rejection, are all factors that lead to inconsistencies in the results. In spite of these problems, the scientifi c optimism for cellular transplantation keeps growing, with the National Institute of Health (USA) devoting additional resources to it.
We describe below some of the neurodegenerative diseases being considered for "treatment" with stem cell transplantation, their results and problems, and the future directions of the approach. In this context, we speculate that the treatment with vitamin C acts in favor of cellular replacement in all disorders listed.
Stem cell transplantation in neurodegenerative disorders
Parkinson's disease
Parkinson's disease (PD) is a progressive neurological disorder that aff ects ~1% of the population over 55 years of age. It is caused by the progressive loss of dopaminergic neurons from the Substantia Nigra and Corpus Striatum, which provokes severe motor dysfunctions, including uncontrollable shaking, rigidity, walking and coordination problems, and at later stages, cognitive and behavioral defi cits. Although the cause(s) of dopaminergic neuronal loss is (are) unknown, a distinctive feature of PD is the accumulation of fi lamentous inclusions known as Lewy bodies, which consist of protein aggregates formed mainly by α-synuclein, ubiquitin and neurofi laments (Trojanowski and Lee, 1998) . The current view is however that Lewy bodies are a consequence and not a cause of the disease. A more recent hypothesis suggests that metabolic alterations in dopaminergic neurons are the primary cause of PD. To support this view, a number of labs have shown that the enzymes involved in the metabolism of dopamine produce elevated quantities of H 2 O 2 (Przedborski et al., 2000) . In the presence of oxygen, these peroxide species form reactive oxygen species (ROS), which at augmented levels alter the health of the neurons. Additionally, dopaminergic cells are highly dependent on adenosine triphosphate, and inhibitors of mitochondrial function (i.e., MPP) accumulate specifi cally in dopaminergic neurons, affecting their ATP production and promoting the generation of ROS (Winklhofer and Haass, 2010). More recently, several genes have been linked to mitochondrial dysfunction and have been consequently implicated in PD (Blandini and Armentero, 2012; Winklhofer and Haass, 2010) . Although the mechanism through which these genes alter free radical generation and mitochondrial function specifically in dopaminergic neurons is not yet clear, the excessive production of free radicals coupled with perturbed mitochondrial function strongly correlates with dopaminergic neuronal death (Betarbet et al., 2002a; Betarbet et al., 2002b; Winklhofer and Haass, 2010) .
Levodopa is currently the only pharmacological option with a recognized eff ect on stopping the progression of PD; it allows the recovery of dopamine levels in the affl icted areas, which in turn alleviates the motor defects observed in PD patients (Dawson et al., 2010) . Unfortunately, the eff ectiveness of the treatment decreases with time (Dawson et al., 2010) . Due to this, and the lack of pharmacological alternatives, stem cell transplantation has emerged as a compelling strategy to restore dopaminergic neurons in PD patients. In theory, stem cells have the potential to generate an unlimited number of dopaminergic neurons. In practice, it has been tremendously diffi cult to produce them (Cao et al., 2001; Li et al., 2007) . By over-expressing genes that encode transcription factors present primarily in dopaminergic neurons, embryonic stem cells have been derived into dopaminergic neurons in vitro (Jacobs et al., 2009; Perrier et al., 2004) . These pioneer results immediately raised the possibility of transplanting dopaminergic neurons in PD animal models (Kriks et al., 2011; Tabar et al., 2008) and patients. Kriks and colleagues (2011) were the fi rst to introduce stem cell-derived dopaminergic neurons into PD mice. Transplanted neurons survived, integrated into the mature neuronal parenchyma and established neural connections with the existent neurons (Kriks et al., 2011) . More importantly, these cellular transplants were able to signifi cantly improve motor function in PD mice (Kriks et al., 2011) . Several labs are now trying to inject stem cell-derived dopaminergic neurons into human PD patients.
Although the results in animal models are quite encouraging, stem cell transplantations have not been exempt of problems. A large number of the transplanted cells often die after the procedure, reducing the possibilities of replacing the damaged cells. In other cases, the newly diff erentiated neurons become pluripotent cells again, and no longer express the identifying dopaminergic factors. A major problem is that the exogenous transplants may generate aggressive tumors, making the treatment strategy quite dangerous. It is therefore fundamental to solve these and other problems before stem cell therapy could be used safely and effi ciently in human patients. It is also of major priority to understand the factors that might regulate stem cell transplantation in PD patients. In this context, experimental evidence suggests that vitamin C might positively modulate stem cell transplantation. First, as an antioxidant, vitamin C can drastically reduce the accumulation of free radicals produced by both the endogenous tissue, and the stem cell-derived neurons exogenously incorporated into the tissue. The scavenging eff ect of vitamin C has an important consequence; it dramatically reduces cell death. Such improvement in survival should have a direct impact on the number of stem cell-derived neurons available for insertion into the affl icted tissue. Thus, vitamin C indirectly modulates neuronal integration. A second role of vitamin C is to directly favor stem cell production and diff erentiation into dopaminergic neurons. The idea is supported by preliminary results in which mouse or human somatic cells incubated with vitamin C signifi cantly increased the induction of stem cells (Esteban et al., 2010; Yan et al., 2001 ), a mechanism mediated at least in part by regulating the activity of histone demethylases, enzymes required for the expression of Nanog (a master transcription factor for stem cell production). In other experiments, vitamin C has been directly implicated in cellular diff erentiation. Stem cells incubated with vitamin C increased the number of cells that acquired a cardiac phenotype (i.e., contractile properties and GATA4, a and b-myosin heavy chain expression). Similarly, it is possible that under appropriate conditions, vitamin C can promote specifi c neuronal differentiation (Figure 5 ). In general, we believe vitamin C is a promising co-adjuvant to achieve successful stem cell transplantation in PD. Acting via currently unknown pathways, vitamin C induces the formation of specifi c cells types (in this case neurons, green), which upon proper integration, recreates the previously defective neuronal network (green and black neurons). Thus, vitamin C might ultimately lead to an improvement of behavioral alterations.
Alzheimer's disease
Alzheimer's disease (AD) is a devastating neurodegenerative disorder. It is characterized by the progressive loss of memory and cognitive function. Although the exact mechanistic cause(s) of AD is (are) unknown, experimental evidence has guided our attention to the accumulation of beta-amyloid peptide (Aβ-plaques) and hyperphosphorylated tau proteins (neurofi brillary tangles, NFTs) (Lambert et al., 1998; Lee et al., 2005) . Animal models of AD in which Aβ plaques or NFT are expressed, have become the standard tools to study the cellular and molecular alterations present in neurons undergoing AD (Morgan et al., 2000; Mucke et al., 2000; Woodruff -Pak, 2008) . Although our understanding has grown signifi cantly in recent years, there is limited treatment for the disease (Morgan et al., 2000) . The main complication for any therapeutical approach is that almost all neurons (i.e., inhibitory and excitatory neurons as well as local or projection neurons) are equally aff ected in AD (Woodruff -Pak, 2008) . Thus, AD has no unique cellular target. A further complication is that AD aff ects not just one brain region but several, including cortex, hippocampus and brain stem neurons.
Stem cell transplantation is considered the restorative solution for Alzheimer's patients. However, transplantation in AD patients is complicated by the factors previously indicated (i.e., variety of cells undergoing degeneration and brain regions affl icted). Despite this fundamental problem, researchers have injected stem cells or stem cell-derived neurons into various brain regions in AD mouse models with the hope of restoring brain function. While in some cases the transplanted animals showed no improvement, in others stem cell transplantation produced a substantial improvement in cognitive function (Blurton-Jones et al., 2009; Marutle et al., 2007) . The mechanisms by which these stem cell transplants achieved behavioral improvements are however controversial; optimistic researchers have suggested that the improvement is due to the replacement of damaged neurons (Marutle et al., 2007) . However, more conservative investigators indicate that the injected stem cells did not replace damaged neurons but instead released trophic factors (e.g., BDNF, brain derived neurotrophic factor; NT-3, neurotrophin 3) that support cell survival and neuronal plasticity (Blurton-Jones et al., 2009) . Further experiments are necessary to clarify such controversy. In any case, the results indicate that stem cell transplantation is a potentially valuable alternative for AD patients. As we indicated previously, stem cell transplantation can be enhanced by treating the patients with vitamin C because it quenches free radicals and promotes survival of the transplanted stem cell-derived neurons ( Figure 5 ). Such improvement in neuronal survival should favor the insertion of the newly transplanted neurons into the affl icted tissue ( Figure 5 ). In addition, vitamin C should also enhance the proliferation and diff erentiation of stem cells (described above). Future experiments are necessary to support our view.
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a fatal and progressive disease in which spinal cord motor neurons die. As motor neurons and their neuromuscular connections degenerate, muscle strength decays, leading to paralysis and respiratory failure (Donkervoort and Siddique, 1993). A number of comprehensive studies have determined that approximately 10% of the ALS cases are caused by inherited genetic defects, while the rest of the cases have no obvious familial background (Blauw et al., 2012) . Of the genes implicated in ALS, some (SOD1) encode proteins present in the mitochondria (e.g., copper-zinc superoxide dismutase type 1, SOD1) while others encode proteins that bind to DNA/RNA sequences (e.g., fused in sarcoma/translocation in liposarcoma, FUS/TLS; and 43kDa-TAR-DNA binding protein; TDP43). Mutations in any of these genes cause ALS. For example, SOD1 mutations (G93A) alone in motor neurons and glial cells or motor neurons can cause their loss (Renton et al., 2011; Traub et al., 2011) . Aberrant mitochondrial function, endoplasmic reticulum stress, axonal transport defects, and the excessive production of free radicals species have been suggested as the main causes of motor neuron degeneration (Papadeas et al., 2011; Philips and Robberecht, 2011; Van Den Bosch et al., 2006; Yamanaka et al., 2008) . How the mutations in TDP-43 and FUS/TLS produce motor neuron death remains less clear. Alterations in the regulation of gene expression, RNA splicing, RNA transport and translation, as well as microRNA processing have all been implicated as causes of the disease (Buratti and Baralle, 2008) . More recently, a new genomic factor was found to be responsible for ALS; the presence of hexanucleotide repeats in a gene known as C9ORF72, which has no known function (DeJesus-Hernandez et al., 2011; Renton et al., 2011) , directly correlates with many ALS cases. Together, these fi ndings have the potential to lead us to signifi cant advances into understanding how the disease develops. Clinically, however there are no options; no drug has been able to stop or even delay ALS progression. For this reason, stem cell transplantation has emerged as a distinctive strategy to replace ALS affl icted motor neurons and glial cells (Kim et al., 2010; Lepore et al., 2008) . Indeed, it has been possible to diff erentiate stem cells into either motor neurons or glial cells in vitro (Dimos et al., 2008; Karumbayaram et al., 2009; Song et al., 2011) . In a transgenic mouse model of ALS, stem cell transplantation delayed the disease progression, reduced motor neuron loss and improved motor function (Lepore et al., 2008) . More recently, clinical trials of human ALS patients treated with either autologous or xenogenous neuronal stem cells are underway.
As with PD and AD, we believe vitamin C treatment could positively favor stem cell transplantation in ALS patients by fi rst reducing the generation of free radicals, which are particularly toxic for motor neurons that contain low amount of molecular scavengers. Therefore, vitamin C should promote the survival of both diff erentiated and transplanted stem cellderived motor neurons ( Figure 5 ). Vitamin C should also help to promote stem cell proliferation, and diff erentiation by the mechanisms previously described (see above). Validation of the predicted adjuvant role of vitamin C in ALS remains to be demonstrated. thank Dr. Marjet Heitzer for critical reading and editing of the manuscript and Msc. Joanna Tereszczuk for technical support in image processing, Center for Advanced Microscopy, CMA Bio Bio (www.cmabiobio.cl).
